Want to see SE:NICA full AI Analyst Report?
NICA Stock Chart & Stats
kr0.74
kr0.03(1.43%)
At close: 4:00 PM EST
kr0.74
kr0.03(1.43%)
Day’s Range― - ―
52-Week Rangekr0.24 - kr2.25
Previous CloseN/A
Volume105.00
Average Volume (3M)373.03K
Market Cap
kr86.80M
Enterprise Valuekr176.85M
Total Cash (Recent Filing)kr19.06M
Total Debt (Recent Filing)kr53.63M
Price to Earnings (P/E)0.7
Beta1.85
Next Earnings
Nov 26, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.35
Shares Outstanding328,769,840
10 Day Avg. Volume403,250
30 Day Avg. Volume373,032
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.04
Price to Sales (P/S)3.26
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)kr141.40M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSharp TTM revenue acceleration indicates improving commercial traction and growing customer demand for Nanologica’s offerings. If sustained, stronger sales can improve operating leverage, support investment in its platform, and move the business closer to scale in pharmaceutical workflows.
Improved Balance SheetThe stronger equity base and moderate leverage provide greater financial flexibility than the company had in weaker periods. This reduces near-term balance-sheet pressure and gives Nanologica more capacity to fund development and commercial expansion while profitability remains under construction.
Specialized Life-Science PlatformThe company addresses specialized purification, separation, and formulation needs within pharmaceutical and life-science workflows. Its focus on engineered silica materials and related technical services can support customer-specific applications and create opportunities for repeat product and project revenue.
Bears Say
Persistent Operating LossesDeeply negative gross and operating profit shows that revenue growth has not yet produced a sustainable underlying business model. Continued losses may restrict reinvestment, increase funding needs, and make future performance dependent on achieving materially better pricing, scale, or cost control.
Negative Cash GenerationNegative operating and free cash flow means the company is not yet funding operations and investment internally. Persistent cash burn can consume financial resources and leave Nanologica reliant on financing until commercial growth translates into recurring cash generation.
Earnings Quality RiskPositive reported net income alongside negative operating cash flow suggests earnings are not yet translating into cash from the core business. This reduces confidence in the durability of current profits and increases the importance of operational improvement for future results.
Nanologica AB News
NICA FAQ
What was Nanologica AB’s price range in the past 12 months?
Nanologica AB lowest stock price was kr0.24 and its highest was kr2.25 in the past 12 months.
What is Nanologica AB’s market cap?
Nanologica AB’s market cap is kr86.80M.
When is Nanologica AB’s upcoming earnings report date?
Nanologica AB’s upcoming earnings report date is Nov 26, 2026 which is in 34 days.
How were Nanologica AB’s earnings last quarter?
Nanologica AB released its earnings results on Aug 31, 2026. The company reported -kr0.06 earnings per share for the quarter.
Is Nanologica AB overvalued?
According to Wall Street analysts Nanologica AB’s price is currently Overvalued.
Does Nanologica AB pay dividends?
Nanologica AB does not currently pay dividends.
What is Nanologica AB’s EPS estimate?
Nanologica AB’s EPS estimate is -0.03.
How many shares outstanding does Nanologica AB have?
Nanologica AB has 328,769,840 shares outstanding.
What happened to Nanologica AB’s price movement after its last earnings report?
Nanologica AB reported an EPS of -kr0.06 in its last earnings report. Following the earnings report the stock price went down -23.061%.
Which hedge fund is a major shareholder of Nanologica AB?
Currently, no hedge funds are holding shares in SE:NICA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanologica AB
Nanologica AB (publ), a nanotechnology company, develops, manufactures, and sells nanoporous silica particles for life science industry in China, India, the United State of America, and internationally. It offers NLAB Saga, a new generation silica for preparative chromatography; and SVEA, a pre-packaged columns for analytical chromatography; and high-performance liquid chromatography, a separation method based on different substances in a solution passing through a column at different paces. The company provides products for the analysis and purification of substances, with a focus on peptides drugs for the treatment of diabetes and obesity. Nanologica AB (publ) was incorporated in 2004 and is headquartered in Södertälje, Sweden.
Technical Analysis
Camurus AB
―
Xbrane Biopharma AB
―
Xspray Pharma AB
―
Spago Nanomedical AB
―
Nanexa AB
―